Notice for asciminib hydrochloride (Novartis Pharmaceuticals Australia Pty Ltd)
Active ingredients
asciminib hydrochloride
Date of review outcome
Lapse date
Type
Priority review
Dosage form(s)
film-coated tablets
Indication
For the treatment of patients 18 years of age and above with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP)
Therapeutic area
Haematology